Wall Street brokerages expect Correvio Pharma Corp (NASDAQ:CORV) to report earnings of ($0.18) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Correvio Pharma’s earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.15). Correvio Pharma posted earnings of ($0.24) per share in the same quarter last year, which indicates a positive year over year growth rate of 25%. The company is scheduled to announce its next quarterly earnings report on Tuesday, March 12th.

According to Zacks, analysts expect that Correvio Pharma will report full year earnings of ($0.48) per share for the current financial year, with EPS estimates ranging from ($0.52) to ($0.45). For the next financial year, analysts forecast that the firm will report earnings of ($0.60) per share, with EPS estimates ranging from ($0.74) to ($0.46). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Correvio Pharma.

Correvio Pharma (NASDAQ:CORV) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.20) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.20). Correvio Pharma had a negative net margin of 68.98% and a negative return on equity of 294.35%. The firm had revenue of $7.01 million for the quarter, compared to analyst estimates of $7.55 million.

A number of research analysts have weighed in on the stock. HC Wainwright set a $11.00 price objective on shares of Correvio Pharma and gave the company a “buy” rating in a research note on Wednesday, November 7th. B. Riley assumed coverage on shares of Correvio Pharma in a research note on Tuesday, December 4th. They issued a “buy” rating and a $7.00 price objective on the stock. Mackie raised shares of Correvio Pharma from a “hold” rating to a “buy” rating in a research note on Friday, October 12th. Finally, ValuEngine raised shares of Correvio Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, September 6th.

Several institutional investors have recently added to or reduced their stakes in CORV. Worth Venture Partners LLC bought a new position in shares of Correvio Pharma in the third quarter valued at $173,000. Royce & Associates LP bought a new position in shares of Correvio Pharma in the third quarter valued at $1,025,000. ARS Investment Partners LLC bought a new position in shares of Correvio Pharma in the third quarter valued at $1,121,000. Renaissance Technologies LLC lifted its stake in shares of Correvio Pharma by 22.1% in the third quarter. Renaissance Technologies LLC now owns 739,248 shares of the company’s stock valued at $2,972,000 after buying an additional 133,825 shares in the last quarter. Finally, Putnam Investments LLC bought a new position in shares of Correvio Pharma in the second quarter valued at $11,688,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Correvio Pharma stock opened at $3.64 on Tuesday. Correvio Pharma has a 1-year low of $1.31 and a 1-year high of $5.24. The company has a debt-to-equity ratio of 4.02, a current ratio of 4.05 and a quick ratio of 3.46.

About Correvio Pharma

Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.

Featured Story: Analyzing a company’s cash flow statement

Get a free copy of the Zacks research report on Correvio Pharma (CORV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.